Medigene AG

Medigene AG will present at ESMO Congress 2024 taking place from September 13-17, 2024 in Barcelona, Spain. Read here the PR: https://lnkd.in/dNpaF_aD More details on the conference here: https://www.esmo.org/ #ESMO, #Platform2Patient, #TCR, #TCRT

Sarcoma is often called the “forgotten cancer.” July marks Sarcoma Awareness Month, dedicated to raising awareness about sarcoma, a rare cancer that develops in the bones and soft tissues, including muscles, fat, blood vessels, and fibrous tissues. Let's focus on raising awareness about sarcoma and promoting research efforts for improved treatments. Medigene AG selected myxoid/round cell liposarcoma, which account for 10-20% of soft tissue sarcomas, as one of the initial clinical indications for its lead program MDG1015. More information around MDG1015: https://lnkd.in/d6k_fakE #Platform2Patient #TCR #TCRT#Sarcoma Awareness

Medigene AG announced today that it has been granted a patent by the Chinese Patent Office for its T cell receptor targeting NY-ESO-1, complementing similar patents already issued in the United States, Japan, South Korea, Taiwan, and Australia. This optimal affinity 3S TCR along with the PD1-41BB costimulatory switch protein forms the core component of the Company's leading program MDG1015. Read here the PR: https://lnkd.in/dVvHK4GZ More information on our lead program MDG1015 here: https://lnkd.in/d6k_fakE #Platform2Patient #TCR #TCRT

Medigene AG presented a detailed overview of its lead candidate MDG1015, a first-in-class 3rd generation TCR-T therapy at the 7th Cell and Gene Therapy In-Depth Focus Summit from June 27-28, 2024, in Beijing, China. In her presentation, Kirsty Crame - van Nierop highlighted Medigene’s lead TCR-T program, MDG1015 which targets the cancer-testis antigens NY-ESO-1 / LAGE-1a and is armored and enhanced by the Company’s PD1-41BB costimulatory switch protein. MDG1015 is scheduled for IND submission in the third quarter of 2024 and CTA submission in the fourth quarter of 2024. Read here the full PR: https://lnkd.in/dGJZN-5W Find more details on MDG1015 here: https://lnkd.in/d6k_fakE Conference details: https://lnkd.in/dv6X9dCX

Medigene will present virtually at the 7th Cell and Gene Therapy In-Depth Focus Summit taking place from June 27-28, 2024, in Beijing, China. The presentation will feature the Company’s lead program MDG1015, a first-in-class third-generation TCR-T therapy. Read here the PR: https://lnkd.in/d5hTQufk Find out more about MDG1015 here:https://lnkd.in/d6k_fakE More details on the conference: https://lnkd.in/dv6X9dCX #Platform2Patient #TCR #TCRT

Today Medigene AG announces lead selection for MDG2021, a TCR-T therapy targeting KRAS G12D-A*11. MDG2021 is the latest program now in preclinical development within Medigene’s library of neoantigens that comprises multiple KRAS mutations and HLAs. Read here the full PR: https://lnkd.in/dhzm-tDj Find out more about our KRAS library here: https://lnkd.in/dR-yASYw #Platform2Patient #TCR #TCRT

Meet Medigene AG at #BIO2024! Our Senior Business Development Director Oscar Irvin-Sellers will attend BIO International Convention in San Diego from June 3-5, 2024. Feel free to directly reach out to Oscar Irvin-Sellers or connect via the BIO One-on-One Partnering system to schedule a meeting.  For more information, please visit the conference website: https://lnkd.in/gMcJ49Eg

We are excited to announce that we have submitted three patents to the European Patent Office for new proprietary technologies to further expand our End-to-End (E2E) Platform: 🔎🧫 𝗢𝘂𝗿 𝗜𝗻𝘁𝗲𝗿𝗳𝗲𝗿𝗼𝗻-𝗴𝗮𝗺𝗺𝗮 (𝗜𝗙𝗡γ) 𝗕𝗶𝗼𝘀𝗲𝗻𝘀𝗼𝗿 enables real-time monitoring and quantification of IFNγ release from cytokine-secreting cells. This provides detailed insights into immune response dynamics that are not possible using commercial tools. 💉 🔍 𝗢𝘂𝗿 𝗵𝗶𝗴𝗵 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗧𝗖𝗥 𝘁𝗿𝗮𝗰𝗸𝗶𝗻𝗴 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀, 𝗨𝗻𝗶𝗧𝗼𝗽𝗲 & 𝗧𝗿𝗮𝗖𝗥, are designed to uniquely tag the #TCR and exactly track its location. This allows precise evaluation of proliferation, persistence, and localization of a TCR-guided cell therapy, both in vitro and in vivo.   These 3 patents will join our group of over 20 different patent families covering Medigene’s 3S (sensitive, specific and safe) TCRs as well as its exclusive #E2E Platform technologies. Read here more: https://lnkd.in/dcb_NgYE #Platform2Patient #TCR #TCRT

Medigene AG announced today the extension of their global research and collaboration agreement with BioNTech SE beyond the initially announced term. We are very pleased about this extension and to continue our collaboration with BioNTech to help patients suffering from solid tumors. This extension will enable the work required for potentially generating novel TCRs against multiple newly nominated antigen targets. With this, BioNTech could further expand its warehouse of TCR candidates.   We had entered the initial 3-year agreement with BioNTech in February of 2022. In addition to the discovery and development of TCRs with our advanced technologies, the agreement also includes non-exclusive licenses for some of our other innovative tools. This includes the PD1-41BB costimulatory switch protein, a powerful tool to help TCR-T cells overcome the hostile tumor microenvironment. Read the full PR here: https://lnkd.in/dc7mkHyX Find out more about our End-to-End Platform here: https://lnkd.in/eDjmquVJ #TME #TCRT 

May is National Cancer Research Month. Join us to showcase how research-driven advancements against cancer are enriching the lives of those impacted by the disease. At Medigene AG, we are committed to generate optimal T cell receptors against both cancer testis antigens and neoantigens, armor and enhance these TCR-T cells to create best-in-class, differentiated TCR-T therapies. Find out more about the End-to-End Technology Platform here: https://lnkd.in/eDjmquVJ Read here more about MDG1015, a first-in-class, 3rd generation TCR-T therapy targeting NY-ESO-1/LAGE-1a : https://lnkd.in/d6k_fakE Read here more about MDG2011, a best-in-class 3rd-generation TCR-T therapy targeting KRAS G12V mutation: https://lnkd.in/dR-yASYw #NCRM24. #CancerResearchMonth #Platform2Patient #TCR #TCRT